Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 27, 2015 6:00 PM ET


Company Overview of Protein Genomics, Inc.

Company Overview

Protein Genomics, Inc. engages in the research, development, and production of biopolymers for applications in wound healing, tissue regeneration, dermal filler, and personal care markets. It produces Elastatropin, a laboratory synthesized form of human tropoelastin, which is a natural precursor of the human elastin in the skin for use in wound healing, anti-aging skin care, and scalp and hair conditioning applications. The company also produces Keracyte, a scalp conditioner that is formulated to stimulate hair follicles to make existing hair shafts thicker, stronger, and longer, as well as contains a proprietary catalytic anti-oxidant prolisel that protects against the damaging effects of U...

2675 West Highway 89A

PMB 1319

Sedona, AZ 86336

United States

Founded in 1993



Key Executives for Protein Genomics, Inc.

Scientific Advisor and Director
Age: 66
Scientific Advisor
Scientific Advisor
Scientific Advisor
Age: 65
Scientific Advisor
Compensation as of Fiscal Year 2015.

Protein Genomics, Inc. Key Developments

American Cryostem Corporation and Protein Genomics, Inc. Form Autogenesis Corporation to Support Development of Unique Stem Cell-Based Wound Products

American CryoStem Corporation announced the formation of Autogenesis Corporation (Autogenesis) as part of its collaborative agreement to develop wound healing products and other cellular therapies with privately-held Protein Genomics (PGen). Owned 50/50 by the Companies, Autogenesis will serve as a dedicated business unit focused on continuing and accelerating the research and development of innovative new products and biotechnologies that combine American CryoStem's ATcells(TM) (adipose derived regenerative cells) and ACSelerate(TM) cell media culture products with PGen's Elastatropin(R) human-based protein materials. Pursuant to the previously announced Memorandum of Understanding entered into by American CryoStem and PGen in September 2012, and having successfully met certain defined clinical milestones, both companies have agreed to form Autogenesis, an entity to which each have licensed their respective technologies. From this point forward, Autogenesis will be responsible for perpetuating research and development of all prospective new products and technologies and retain ownership of any future intellectual property which results from the combination of ATcells, ACSelerate and Elastatropin.

Similar Private Companies By Industry

Company Name Region
TriStar Technology Group, LLC United States
Traversa Therapeutics, Inc. United States
Biomedica Inc. United States
CoTherix, Inc. United States
Femina Pharma Incorporated United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Protein Genomics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at